Courtney DiNardo, MD
M.D. Anderson Cancer Center · Abramson Cancer Center at Penn Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
17
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
0
PubMed author-name match
Trials
Studies that name Courtney DiNardo, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:12 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07411586 · Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid LeukemiaM.D. Anderson Cancer Center · active not recruiting · Acute Myeloid Leukemia · principal investigator
- Ph2NCT07032727 · Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway MutationsM.D. Anderson Cancer Center · recruiting · Targeted Therapy, IDH1-Mutated Malignancies, Mutations · principal investigator
- Ph1/Ph2NCT06664879 · ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform TrialM.D. Anderson Cancer Center · active not recruiting · AML · principal investigator
- Ph1NCT06616636 · A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)M.D. Anderson Cancer Center · recruiting · Myelodysplastic Syndrome, Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT06445959 · Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor OlutasidenibM.D. Anderson Cancer Center · recruiting · Mutant IDH1 Inhibitor Olutasidenib · principal investigator
- Ph2NCT06261060 · Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet DisorderM.D. Anderson Cancer Center · recruiting · Familial Platelet Disorder, Hematopoietic · principal investigator
- Ph1/Ph2NCT04874194 · Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1M.D. Anderson Cancer Center · terminated · Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT04774393 · Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaM.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
- Ph2NCT04493164 · CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome, Myeloproliferative Neoplasm · principal investigator
- Ph1/Ph2NCT03634228 · Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid LeukemiaM.D. Anderson Cancer Center · terminated · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT03471260 · Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesM.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm, Myelodysplastic Syndrome · principal investigator
- Ph2NCT02469415 · Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph2NCT02302846 · Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in RemissionM.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph2NCT02010645 · Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph2NCT01932710 · A Feasibility Study of Prophylactic White Blood Cell TransfusionsM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT01893372 · Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- N/ANCT01385150 · Biomarkers in Blood Samples From Patients With Acute Myeloid LeukemiaEastern Cooperative Oncology Group · completed · Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.